Article
Inferior outcome after allogeneic transplant in first remission in high-risk AML patients who required more than two cycles of induction therapy.
American journal of hematology - 1 Aug 2015
Lim Sara J, Lim Matthew J, Raptis Anastasios, Hou Jing-Zhou, Farah Rafic, Marks Stanley M, Im Annie, Dorritie Kathleen, Sehgal Alison, Agha Mounzer, Felgar Raymond, Lim Seah H
Abstract excerpt
While some patients with high-risk acute myeloid leukemia (AML) require one or two cycles of induction chemotherapy to achieve a complete remission (CR), others require more than two cycles. We examined the outcomes of patients with high-risk AML who received allogeneic HPC transplant in CR1. Forty five consecutive high-risk AML patients in CR1 were included. All 45 patients had adverse cytogenetics, FLT 3...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.